Can you specify the date of apotex's ruxolitinib application submission?

What was the exact filing date for Apotex’s ruxolitinib ANDA?

Apotex submitted its abbreviated new drug application for a generic version of ruxolitinib to the FDA on 22 January 2021.

Why did Apotex file an ANDA before the brand patents expired?

The company targeted the first opportunity to challenge remaining exclusivity and capture early market share once any blocking patents were cleared or invalidated.

How long does FDA review of a ruxolitinib ANDA typically take?

Review timelines for complex generic oncology drugs average 30–36 months, with Apotex’s filing now in its third year of agency evaluation.

Can Apotex launch before all patents expire?

Launch is possible only after the last blocking patent expires or after a successful patent challenge; current listed expiry dates for ruxolitinib patents run into 2028–2030.

Who holds the remaining patents on ruxolitinib?

Incyte Corporation owns the composition-of-matter and method-of-use patents that still protect Jakafi, the reference listed drug.

What happens if Apotex’s application receives tentative approval?

Tentative approval would allow Apotex to launch immediately once any remaining regulatory or patent barriers are removed, often within days of final patent expiry.

Are other companies also seeking generic ruxolitinib?

At least five additional ANDA filers, including Teva and Mylan, have submitted applications and are competing for first-to-file or shared exclusivity positions.

When does the key ruxolitinib patent expire?

The primary U.S. composition-of-matter patent (US 7,598,257) expires on 3 December 2028, subject to any pediatric extensions or settlements.